Jim Cramer Notes Pfizer (PFE) Has “Got a Lot of Stuff in the Pipeline”

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s latest stock calls as he discussed the bullish AI investment thesis amid the Iran conflict. While Pfizer was not relevant for the AI theme, when a caller inquired about the stock, Cramer said:

Okay… Pfizer is not an espresso. Pfizer is more like Nescafé, but that’s okay. It’s at $26. It yields 6.4%. It’s got a lot of stuff in the pipeline.

Pfizer Inc. (NYSE:PFE) develops and sells medicines and vaccines for several health conditions, including heart disease, infections, COVID-19, and rare diseases. Cramer talked about the stock during the Squawk on the Street episode aired on January 12, as he commented:

Pfizer, you know, principal vaccine company in the country. I think we have to accept Carl that the vaccine business is under fire. I don’t think that Dr. Bourla is ready for a fight with RFK Jr. I think RFK Jr. wins on this. Let’s see what Pfizer has to say, cause they actually have a lot of important vaccines that maybe should be called into question.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.